A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD.

Trial Profile

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs AZD 1446 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 May 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Planned End Date changed from 1 Oct 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top